- Conditions
- Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
- Interventions
- High Dose NT-501 implant, Low Dose NT-501 implant, Sham
- Combination Product · Other
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
- Conditions
- MacTel (Macular Telangiectasia) Type 2
- Interventions
- Ciliary neurotrophic factor (CNTF), Surgery
- Biological · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- NT-501, Sham Procedure
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- NT-501/revakinagene taroretcel-lwey
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 23
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Low Dose NT-501, High Dose NT-501
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
- Conditions
- Eye Disease, Achromatopsia
- Interventions
- NT-501 CNTF-releasing implant
- Biological
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glaucoma
- Interventions
- NT-501 ECT implant, Sham
- Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- Ciliary neurotrophic factor (CNTF), Sham procedure, NT-501 Implant, NT-501 Implant procedure
- Biological · Procedure · Device
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
- Interventions
- NT-501, Sham
- Drug · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501, Sham
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Colorado Springs, Colorado • Atlanta, Georgia + 18 more
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501 CNTF Implant
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Grand Rapids, Michigan • Bellaire, Texas
- Conditions
- Idiopathic Juxtafoveal Telangiectasia
- Interventions
- NT-501 implant
- Biological
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Cleveland, Ohio
- Conditions
- Retinitis Pigmentosa
- Interventions
- NT-501
- Drug
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Ciliary Neurotrophic Factor Implant NT-501
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland